BeOne Medicines AG (ONC)

Market Cap	33.43B +32.5%
Revenue (ttm)	5.34B +40.2%
Net Income	286.93M
EPS	2.47
Shares Out	110.94M
PE Ratio	121.99
Forward PE	54.73
Dividend	n/a
Ex-Dividend Date	n/a

Volume	281,693
Open	292.50
Previous Close	292.94
Day's Range	290.93 - 301.49
52-Week Range	196.45 - 385.22
Beta	0.52
Analysts	Strong Buy
Price Target	386.70 (+28.34%)
Earnings Date	Feb 26, 2026

About ONC

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients w...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 12,000
• Stock Exchange: NASDAQ
• Ticker Symbol: ONC
• Website: https://beonemedicines.com

Analyst Summary

According to 10 analysts, the average rating for ONC stock is "Strong Buy." The 12-month stock price target is $386.7, which is an increase of 28.34% from the latest price.

Price Target

$386.7

(28.34% upside)

Analyst Consensus: Strong Buy